Continuing Increased Access to Buprenorphine in the United States Via Telemedicine After COVID-19

This is an academic paper that provides commentary on the barriers and disparities of buprenorphine prescribing, the changes in buprenorphine delivery during the coronavirus pandemic, and how sustaining these changes long-term will lead to better outcomes for those with opioid use disorder. 

Continuum of Care
Response Approach
COVID / Coronavirus related
Medications for Opioid Use Disorder

Davis, C.S., Samuels, E.A. (2020). Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 [published online ahead of print, 2020 Aug 15]. Int J Drug Policy, 102905.